Skip to main content
Top
Published in: BMC Health Services Research 1/2009

Open Access 01-12-2009 | Research article

The economic costs and health-related quality of life of people with HIV/AIDS in the Canary Islands, Spain

Authors: Julio Lopez-Bastida, Juan Oliva-Moreno, Lilisbeth Perestelo-Perez, Pedro Serrano-Aguilar

Published in: BMC Health Services Research | Issue 1/2009

Login to get access

Abstract

Background

The objective was to determine the economic burden, as well as the impact on HRQOL for people with HIV/AIDS in Spain in 2003.

Methods

A cross-sectional study of 572 people with HIV were recruited from outpatient clinics in the Canary Islands, Spain. Demographic, health resources utilization, indirect costs and quality of life data were collected through medical records and questionnaires filled out by people with HIV. HRQOL was measured with two generic questionnaires: SF-36 and EQ-5D.

Results

In 2003 annual costs of caring for patients with asymptomatic HIV, symptomatic HIV and AIDS were €10,351, €14,489 and €15,750, respectively. The HRQOL with the EQ-5D was 0.78. SF-36 summary results for physical and mental health were 48.30 and 38.80, respectively.

Conclusion

HIV/AIDS represent a high economic impact from society point of view. the structure of health care costs have changed due to these new drugs, increasing the weight of pharmaceutical treatment over total costs and decreasing the importance of inpatient care costs. In spite of the therapeutic improvements, labour losses/indirect costs still represent a high cost. Costs and HRQOL were strongly associated with severity. Although the latest drug developments have not yet been able to find the definitive cure, they have allowed an improvement in expectancy of life and in the HRQOL of the patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fauci AS: The AIDS Epidemic. Considerations for the 21st Century. N Engl J Med. 1999, 14: 1046-1050. 10.1056/NEJM199909303411406.CrossRef Fauci AS: The AIDS Epidemic. Considerations for the 21st Century. N Engl J Med. 1999, 14: 1046-1050. 10.1056/NEJM199909303411406.CrossRef
2.
go back to reference Walker N, Grassly NC, Garnett GP, Stanecki KA, Ghys PD: Estimating the global burden of HIV/AIDS: what do we really know about the HIV pandemic?. Lancet. 2004, 363: 2180-2185. 10.1016/S0140-6736(04)16511-2.CrossRefPubMed Walker N, Grassly NC, Garnett GP, Stanecki KA, Ghys PD: Estimating the global burden of HIV/AIDS: what do we really know about the HIV pandemic?. Lancet. 2004, 363: 2180-2185. 10.1016/S0140-6736(04)16511-2.CrossRefPubMed
3.
go back to reference Beck E, Miners A, Tolley K: The cost of HIV treatment and care. A global review. Pharmacoeconomics. 2001, 19: 13-39. 10.2165/00019053-200119010-00002.CrossRefPubMed Beck E, Miners A, Tolley K: The cost of HIV treatment and care. A global review. Pharmacoeconomics. 2001, 19: 13-39. 10.2165/00019053-200119010-00002.CrossRefPubMed
4.
go back to reference Castilla J, de la Fuente L: Trends in the number of human immunodeficiency virus infected persons and AIDS cases in Spain: 1980–1998. Med Clin (Barc). 2000, 115: 85-89.CrossRef Castilla J, de la Fuente L: Trends in the number of human immunodeficiency virus infected persons and AIDS cases in Spain: 1980–1998. Med Clin (Barc). 2000, 115: 85-89.CrossRef
5.
go back to reference Encuesta Hospitalaria del VIH/SIDA, 2001, 2002, 2003: Plan Nacional del SIDA. 2005, Ministerio de Sanidad y Consumo. Madrid Encuesta Hospitalaria del VIH/SIDA, 2001, 2002, 2003: Plan Nacional del SIDA. 2005, Ministerio de Sanidad y Consumo. Madrid
6.
go back to reference Sterne JA, Hernan MA, Ledergerber B, Tilling K, Weber R, Sendi P, Rickenbach M, Robins J, Egger M, Swiss HIV Cohort Study: Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005, 366: 378-384. 10.1016/S0140-6736(05)67022-5.CrossRefPubMed Sterne JA, Hernan MA, Ledergerber B, Tilling K, Weber R, Sendi P, Rickenbach M, Robins J, Egger M, Swiss HIV Cohort Study: Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005, 366: 378-384. 10.1016/S0140-6736(05)67022-5.CrossRefPubMed
7.
go back to reference Garattini L, Tediosi F, Di Cintio E, Yin D, Parazzini F, Gruppo di Studio ARCA (AIDS Resources and Costs Analysis): Resource utilization and hospital cost of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy. AIDS Care. 2001, 13: 733-741. 10.1080/09540120120076896.CrossRefPubMed Garattini L, Tediosi F, Di Cintio E, Yin D, Parazzini F, Gruppo di Studio ARCA (AIDS Resources and Costs Analysis): Resource utilization and hospital cost of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy. AIDS Care. 2001, 13: 733-741. 10.1080/09540120120076896.CrossRefPubMed
8.
go back to reference Merito M, Bonaccorsi A, Pammolli F, Riccaboni M, Baio G, Arici C, D'Arminio Monforted A, Pezzottie P, Corsinif D, Tramaring A, Caudah R, for the I.CO.N.A. Study Group: Economic evaluation of HIV treatments: the I.CO.N.A. Cohort study. Health Policy. 2005, 74: 304-313. 10.1016/j.healthpol.2005.01.016.CrossRefPubMed Merito M, Bonaccorsi A, Pammolli F, Riccaboni M, Baio G, Arici C, D'Arminio Monforted A, Pezzottie P, Corsinif D, Tramaring A, Caudah R, for the I.CO.N.A. Study Group: Economic evaluation of HIV treatments: the I.CO.N.A. Cohort study. Health Policy. 2005, 74: 304-313. 10.1016/j.healthpol.2005.01.016.CrossRefPubMed
9.
go back to reference Sendi P, Schellenberg F, Ungsedhapand C, Kaufmann GR, Bucher HC, Weber R, Battegay M, Swiss HIV Cohort Study: Productivity costs and determinants of productivity in HIV-infected patients. Clin Ther. 2004, 26: 791-800. 10.1016/S0149-2918(04)90080-X.CrossRefPubMed Sendi P, Schellenberg F, Ungsedhapand C, Kaufmann GR, Bucher HC, Weber R, Battegay M, Swiss HIV Cohort Study: Productivity costs and determinants of productivity in HIV-infected patients. Clin Ther. 2004, 26: 791-800. 10.1016/S0149-2918(04)90080-X.CrossRefPubMed
10.
go back to reference Oliva J, Roa C, del Llano J: Indirect costs in ambulatory patients with HIV/AIDS in Spain: a pilot study. Pharmacoeconomics. 2003, 21: 1113-1121. 10.2165/00019053-200321150-00005.CrossRefPubMed Oliva J, Roa C, del Llano J: Indirect costs in ambulatory patients with HIV/AIDS in Spain: a pilot study. Pharmacoeconomics. 2003, 21: 1113-1121. 10.2165/00019053-200321150-00005.CrossRefPubMed
11.
go back to reference Hays R, Cunningham W, Sherbourne C, Wilson I, Wu A, Cleary P, McCaffrey D, Fleishman J, Crystal S, Collins R, Eggan F, Shapiro M, Bozzette S: Health-related quality of life in patients with human immunodeficiency virus infection in the United States: results from the HIV Cost and Services Utilization Study. Am J Med. 2000, 108: 714-722. 10.1016/S0002-9343(00)00387-9.CrossRefPubMed Hays R, Cunningham W, Sherbourne C, Wilson I, Wu A, Cleary P, McCaffrey D, Fleishman J, Crystal S, Collins R, Eggan F, Shapiro M, Bozzette S: Health-related quality of life in patients with human immunodeficiency virus infection in the United States: results from the HIV Cost and Services Utilization Study. Am J Med. 2000, 108: 714-722. 10.1016/S0002-9343(00)00387-9.CrossRefPubMed
12.
go back to reference Ancelle-Park R: Expanded European AIDS case definition. Lancet. 1993, 341: 441-10.1016/0140-6736(93)93040-8.CrossRefPubMed Ancelle-Park R: Expanded European AIDS case definition. Lancet. 1993, 341: 441-10.1016/0140-6736(93)93040-8.CrossRefPubMed
13.
go back to reference Hodgson T, Meiners M: Cost-of-illness methodology: a guide to current practices and procedures. The Milbank Memorial Fund Quarterly. Health Soc. 1982, 60: 429-462. 10.2307/3349801.CrossRef Hodgson T, Meiners M: Cost-of-illness methodology: a guide to current practices and procedures. The Milbank Memorial Fund Quarterly. Health Soc. 1982, 60: 429-462. 10.2307/3349801.CrossRef
14.
go back to reference Kobelt G: Health Economics: An Introduction to Economic Evaluation. 2002, Office of Health Economics. London, Second Kobelt G: Health Economics: An Introduction to Economic Evaluation. 2002, Office of Health Economics. London, Second
15.
go back to reference Agencia de Calidad del Sistema Nacional de Salud. Instituto de Información Sanitaria. Pesos Españoles y Costes – Años 1999–2003: 2006, Ministerio de Sanidad y Consumo. Madrid Agencia de Calidad del Sistema Nacional de Salud. Instituto de Información Sanitaria. Pesos Españoles y Costes – Años 1999–2003: 2006, Ministerio de Sanidad y Consumo. Madrid
16.
go back to reference Centro de Estudios en Economía de la Salud y Política Social: Base de datos de costes sanitarios SOIKOS, versión 2.1. Barcelona. 2004 Centro de Estudios en Economía de la Salud y Política Social: Base de datos de costes sanitarios SOIKOS, versión 2.1. Barcelona. 2004
17.
go back to reference Max W, Rice D, Mackenzie E: The lifetime cost of injury. Inquiry. 1990, 27: 332-343.PubMed Max W, Rice D, Mackenzie E: The lifetime cost of injury. Inquiry. 1990, 27: 332-343.PubMed
18.
go back to reference Ware J, Sherbourne C: The MOS 36 Item Short-Form Health Status survey (SF-36): l. Conceptual framework and item selection. Med Care. 1992, 30: 473-483. 10.1097/00005650-199206000-00002.CrossRefPubMed Ware J, Sherbourne C: The MOS 36 Item Short-Form Health Status survey (SF-36): l. Conceptual framework and item selection. Med Care. 1992, 30: 473-483. 10.1097/00005650-199206000-00002.CrossRefPubMed
19.
go back to reference Brooks R: EuroQol: the current state of play. Health Policy. 1996, 37: 53-72. 10.1016/0168-8510(96)00822-6.CrossRefPubMed Brooks R: EuroQol: the current state of play. Health Policy. 1996, 37: 53-72. 10.1016/0168-8510(96)00822-6.CrossRefPubMed
20.
go back to reference Alonso J, Prieto L, Anto J: The Spanish version of the SF-36 Health Survey (the SF-36 health questionnaire): an instrument for measuring clinical results. Med Clin (Barc). 1995, 104: 771-776. Alonso J, Prieto L, Anto J: The Spanish version of the SF-36 Health Survey (the SF-36 health questionnaire): an instrument for measuring clinical results. Med Clin (Barc). 1995, 104: 771-776.
21.
go back to reference Vilagut G, Ferrer M, Rajmil L, Rebollo P, Permanyer-Miralda G, Quintana J, Santed R, Valderas JM, Ribera A, Domingo-Salvany A, Alonso J: The Spanish version of the Short Form 36 Health Survey: a decade of experience and new developments. Gac Sanit. 2005, 19: 135-150. 10.1157/13074369.CrossRefPubMed Vilagut G, Ferrer M, Rajmil L, Rebollo P, Permanyer-Miralda G, Quintana J, Santed R, Valderas JM, Ribera A, Domingo-Salvany A, Alonso J: The Spanish version of the Short Form 36 Health Survey: a decade of experience and new developments. Gac Sanit. 2005, 19: 135-150. 10.1157/13074369.CrossRefPubMed
22.
go back to reference Badia X, Roset M, Montserrat S, Herdman M, Segura A: The Spanish version of EuroQol: a description and its applications. European Quality of Life scale. Med Clin (Barc). 1999, 112 (Suppl 1): 79-85. Badia X, Roset M, Montserrat S, Herdman M, Segura A: The Spanish version of EuroQol: a description and its applications. European Quality of Life scale. Med Clin (Barc). 1999, 112 (Suppl 1): 79-85.
23.
go back to reference Greiner W, Weijnen T, Nieuwenhuizen M, Oppe S, Badia X, Busschbach J, Buxton M, Dolan P, Kind P, Krabbe P: A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ. 2003, 4: 222-231. 10.1007/s10198-003-0182-5.CrossRefPubMed Greiner W, Weijnen T, Nieuwenhuizen M, Oppe S, Badia X, Busschbach J, Buxton M, Dolan P, Kind P, Krabbe P: A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ. 2003, 4: 222-231. 10.1007/s10198-003-0182-5.CrossRefPubMed
24.
go back to reference Dolan P: Modeling valuations for EuroQol health states. Med Care. 1997, 35: 1095-1108. 10.1097/00005650-199711000-00002.CrossRefPubMed Dolan P: Modeling valuations for EuroQol health states. Med Care. 1997, 35: 1095-1108. 10.1097/00005650-199711000-00002.CrossRefPubMed
25.
go back to reference Levy A, James D, Johnston K, Hogg R, Harrigan P, Harrigan B, Sobolev B, Montaner J: The direct costs of HIV/AIDS care. Lancet Infectious Diseases. 2006, 6 (3): 171-177. 10.1016/S1473-3099(06)70413-3.CrossRefPubMed Levy A, James D, Johnston K, Hogg R, Harrigan P, Harrigan B, Sobolev B, Montaner J: The direct costs of HIV/AIDS care. Lancet Infectious Diseases. 2006, 6 (3): 171-177. 10.1016/S1473-3099(06)70413-3.CrossRefPubMed
26.
go back to reference Hellinger FJ: The Lifetime Cost of Treating a Person with HIV. JAMA. 1993, 270 (4): 474-8. 10.1001/jama.270.4.474.CrossRefPubMed Hellinger FJ: The Lifetime Cost of Treating a Person with HIV. JAMA. 1993, 270 (4): 474-8. 10.1001/jama.270.4.474.CrossRefPubMed
27.
go back to reference Hellinger FJ: Economic Models of Antiretroviral Therapy: Searching for the Optimal Strategy. Pharmacoeconomics. 2006, 24 (7): 631-42. 10.2165/00019053-200624070-00002.CrossRefPubMed Hellinger FJ: Economic Models of Antiretroviral Therapy: Searching for the Optimal Strategy. Pharmacoeconomics. 2006, 24 (7): 631-42. 10.2165/00019053-200624070-00002.CrossRefPubMed
28.
go back to reference Krentz H, Auld M, Gill M, HIV Economic Study Group: The changing direct costs of medical care for patients with HIV/AIDS, 1995–2001. Can Med Assoc J. 2003, 169: 106-110. Krentz H, Auld M, Gill M, HIV Economic Study Group: The changing direct costs of medical care for patients with HIV/AIDS, 1995–2001. Can Med Assoc J. 2003, 169: 106-110.
29.
go back to reference Stoll M, Claes C, Schulte E, Graf von der Schulenburg J, Schmidt R: Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART. Eur J Med Res. 2002, 7: 463-471.PubMed Stoll M, Claes C, Schulte E, Graf von der Schulenburg J, Schmidt R: Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART. Eur J Med Res. 2002, 7: 463-471.PubMed
30.
go back to reference Flori Y, le Vaillant M: Use and cost of antiretrovirals in France 1995–2000: an analysis based on the Medical Dossier on Human Immunodeficiency (release 2) database. Pharmacoeconomics. 2004, 22: 1061-1070. 10.2165/00019053-200422160-00003.CrossRefPubMed Flori Y, le Vaillant M: Use and cost of antiretrovirals in France 1995–2000: an analysis based on the Medical Dossier on Human Immunodeficiency (release 2) database. Pharmacoeconomics. 2004, 22: 1061-1070. 10.2165/00019053-200422160-00003.CrossRefPubMed
31.
go back to reference Basuyau F, Josset V, Merle V, Czernichow P: Case fatality and health care costs in HIV-infected patients: evolution from 1992 to 2000 at Rouen University Hospital, France. Int J STD AIDS. 2004, 15: 679-684. 10.1258/0956462041944420.CrossRefPubMed Basuyau F, Josset V, Merle V, Czernichow P: Case fatality and health care costs in HIV-infected patients: evolution from 1992 to 2000 at Rouen University Hospital, France. Int J STD AIDS. 2004, 15: 679-684. 10.1258/0956462041944420.CrossRefPubMed
32.
go back to reference Antoñanzas F, Antón F, Juárez C: Cost of AIDS treatment calculation in Spain by simulation techniques. Med Clin (Barc). 1995, 104: 568-572. Antoñanzas F, Antón F, Juárez C: Cost of AIDS treatment calculation in Spain by simulation techniques. Med Clin (Barc). 1995, 104: 568-572.
33.
go back to reference Mompo C, Abbas I, Santin M, Rovira J, Anton F, Tomas C, Antoñanzas F: Health care resources utilization in HIV-infected patients: creation of a database and cost results. Gac Sanit. 2000, 14: 39-47.CrossRefPubMed Mompo C, Abbas I, Santin M, Rovira J, Anton F, Tomas C, Antoñanzas F: Health care resources utilization in HIV-infected patients: creation of a database and cost results. Gac Sanit. 2000, 14: 39-47.CrossRefPubMed
34.
go back to reference Koopmanschap MA, van Ineveld BM: Towards a new approach for estimating indirect costs of disease. Soc Sci Med. 1992, 34: 1005-1010. 10.1016/0277-9536(92)90131-9.CrossRefPubMed Koopmanschap MA, van Ineveld BM: Towards a new approach for estimating indirect costs of disease. Soc Sci Med. 1992, 34: 1005-1010. 10.1016/0277-9536(92)90131-9.CrossRefPubMed
35.
go back to reference Sach T, Whynes D: Measuring indirect costs: is there a problem?. Appl Health Econ Health Policy. 2003, 2: 135-139.PubMed Sach T, Whynes D: Measuring indirect costs: is there a problem?. Appl Health Econ Health Policy. 2003, 2: 135-139.PubMed
36.
go back to reference Grossman M: The human capital model of the demand for health. Handbook of health economics. Edited by: Culyer AJ, Newhouse JP. 2000, Amsterdam: North-Holland Grossman M: The human capital model of the demand for health. Handbook of health economics. Edited by: Culyer AJ, Newhouse JP. 2000, Amsterdam: North-Holland
37.
go back to reference Liljas B: How to calculate indirect costs in economic evaluation. Pharmacoeconomics. 1998, 13: 1-7. 10.2165/00019053-199813010-00001.CrossRefPubMed Liljas B: How to calculate indirect costs in economic evaluation. Pharmacoeconomics. 1998, 13: 1-7. 10.2165/00019053-199813010-00001.CrossRefPubMed
38.
go back to reference Scitovsky A, Rice D: Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991. Public Health Rep. 1987, 102: 5-17.PubMedPubMedCentral Scitovsky A, Rice D: Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991. Public Health Rep. 1987, 102: 5-17.PubMedPubMedCentral
39.
go back to reference Yelin E, Greenblatt R, Hollander H, McMaster J: The impact of HIV-related illness on employment. Am J Public Health. 1991, 81: 79-84. 10.2105/AJPH.81.1.79.CrossRefPubMedPubMedCentral Yelin E, Greenblatt R, Hollander H, McMaster J: The impact of HIV-related illness on employment. Am J Public Health. 1991, 81: 79-84. 10.2105/AJPH.81.1.79.CrossRefPubMedPubMedCentral
40.
go back to reference Massagli M, Weissman J, Seage G, Epstein A: Correlates of employment after AIDS diagnosis in the Boston Health Study. Am J Public Health. 1994, 84: 1976-1981. 10.2105/AJPH.84.12.1976.CrossRefPubMedPubMedCentral Massagli M, Weissman J, Seage G, Epstein A: Correlates of employment after AIDS diagnosis in the Boston Health Study. Am J Public Health. 1994, 84: 1976-1981. 10.2105/AJPH.84.12.1976.CrossRefPubMedPubMedCentral
41.
go back to reference Leigh J, Lubeck D, Farnham P, Fries J: Potential and actual workdays lost among patients with HIV. J Acquir Immune Defic Syndr Hum Retrovirol. 1995, 8: 392-398.CrossRefPubMed Leigh J, Lubeck D, Farnham P, Fries J: Potential and actual workdays lost among patients with HIV. J Acquir Immune Defic Syndr Hum Retrovirol. 1995, 8: 392-398.CrossRefPubMed
42.
go back to reference Laursen E, Larsen L: Socio-economic status of AIDS patients. Scand J Soc Med. 1995, 23: 189-192.PubMed Laursen E, Larsen L: Socio-economic status of AIDS patients. Scand J Soc Med. 1995, 23: 189-192.PubMed
43.
go back to reference Dray-Spira R, Lert F, Marimoutou C, Bouhnik AD, Obadia Y: Socio-economic conditions, health status and employment among persons living with HIV/AIDS in France in 2001. AIDS Care. 2003, 15: 739-748. 10.1080/09540120310001618595.CrossRefPubMed Dray-Spira R, Lert F, Marimoutou C, Bouhnik AD, Obadia Y: Socio-economic conditions, health status and employment among persons living with HIV/AIDS in France in 2001. AIDS Care. 2003, 15: 739-748. 10.1080/09540120310001618595.CrossRefPubMed
44.
go back to reference Rabkin J, McElhiney M, Ferrando S, Van Gorp W, Lin S: Predictors of employment of men with HIV/AIDS: a longitudinal study. Psychosom Med. 2004, 66: 72-78. 10.1097/01.PSY.0000108083.43147.6D.CrossRefPubMed Rabkin J, McElhiney M, Ferrando S, Van Gorp W, Lin S: Predictors of employment of men with HIV/AIDS: a longitudinal study. Psychosom Med. 2004, 66: 72-78. 10.1097/01.PSY.0000108083.43147.6D.CrossRefPubMed
45.
go back to reference Goldman D, Bao Y: Effective HIV treatment and the employment of HIV (+) adults. Health Serv Res. 2004, 39: 1691-1712. 10.1111/j.1475-6773.2004.00313.x.CrossRefPubMedPubMedCentral Goldman D, Bao Y: Effective HIV treatment and the employment of HIV (+) adults. Health Serv Res. 2004, 39: 1691-1712. 10.1111/j.1475-6773.2004.00313.x.CrossRefPubMedPubMedCentral
46.
go back to reference Bernell S, Shinogle J: The relationship between HAART use and employment for HIV-positive individuals: an empirical analysis and policy outlook. Health Policy. 2005, 71: 255-264. 10.1016/j.healthpol.2004.08.012.CrossRefPubMed Bernell S, Shinogle J: The relationship between HAART use and employment for HIV-positive individuals: an empirical analysis and policy outlook. Health Policy. 2005, 71: 255-264. 10.1016/j.healthpol.2004.08.012.CrossRefPubMed
47.
go back to reference Auld M: Disentangling the effects of morbidity and life expectancy on labour market outcomes. Health Econ. 2002, 11: 471-483. 10.1002/hec.753.CrossRefPubMed Auld M: Disentangling the effects of morbidity and life expectancy on labour market outcomes. Health Econ. 2002, 11: 471-483. 10.1002/hec.753.CrossRefPubMed
48.
go back to reference Carballo E, Cadarso-Suarez C, Carrera I, Fraga J, de la Fuente J, Ocampo A, Ojea R, Prieta A: Assessing relationships between health-related quality of life and adherence to antiretroviral therapy. Qual Life Res. 2004, 13: 587-599. 10.1023/B:QURE.0000021315.93360.8b.CrossRefPubMed Carballo E, Cadarso-Suarez C, Carrera I, Fraga J, de la Fuente J, Ocampo A, Ojea R, Prieta A: Assessing relationships between health-related quality of life and adherence to antiretroviral therapy. Qual Life Res. 2004, 13: 587-599. 10.1023/B:QURE.0000021315.93360.8b.CrossRefPubMed
49.
go back to reference Wu A, Mathews W, Brysk L, Atkinson J, Grant I, Abramson I, Kennedy C, McCuchan J, Spector S, Richman D: Quality of life in a placebo-controlled trial of zidovudine in patients with AIDS and AIDS-related complex. J Acquir Immune Defic Syndr. 1990, 3: 683-690.PubMed Wu A, Mathews W, Brysk L, Atkinson J, Grant I, Abramson I, Kennedy C, McCuchan J, Spector S, Richman D: Quality of life in a placebo-controlled trial of zidovudine in patients with AIDS and AIDS-related complex. J Acquir Immune Defic Syndr. 1990, 3: 683-690.PubMed
50.
go back to reference Shahriar J, Delate T, Hays R, Coons S: Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease. Health Qual Life Outcomes. 2003, 1: 25-10.1186/1477-7525-1-25.CrossRefPubMedPubMedCentral Shahriar J, Delate T, Hays R, Coons S: Commentary on using the SF-36 or MOS-HIV in studies of persons with HIV disease. Health Qual Life Outcomes. 2003, 1: 25-10.1186/1477-7525-1-25.CrossRefPubMedPubMedCentral
51.
go back to reference Palomo L, Ortún V, García-Benavides F, Marzquez-Calderón S: Los desajustes en la salud en el mundo desarrollado. Edited by: Hurope SL. 2006, Informe Sespas. Madrid Palomo L, Ortún V, García-Benavides F, Marzquez-Calderón S: Los desajustes en la salud en el mundo desarrollado. Edited by: Hurope SL. 2006, Informe Sespas. Madrid
52.
go back to reference BOE: LEY 16/de 28 de mayo, de cohesión y calidad del Sistema Nacional de Salud. Boletín Oficial del Estado. 2003, 128: 20567-20588. BOE: LEY 16/de 28 de mayo, de cohesión y calidad del Sistema Nacional de Salud. Boletín Oficial del Estado. 2003, 128: 20567-20588.
54.
go back to reference Grupo de estudios de Sida (GESIDA) y Consejo Asesor Clínico (CAC) del Plan Nacional sobre el SIDA (PNS) del Ministerio de Sanidad y Consumo (MSC): Recomendaciones de GESIDA/PNS respecto al tratamiento antirretroviral en pacientes adultos infectados por el VIH. 2005, GESIDA y MSC. Madrid Grupo de estudios de Sida (GESIDA) y Consejo Asesor Clínico (CAC) del Plan Nacional sobre el SIDA (PNS) del Ministerio de Sanidad y Consumo (MSC): Recomendaciones de GESIDA/PNS respecto al tratamiento antirretroviral en pacientes adultos infectados por el VIH. 2005, GESIDA y MSC. Madrid
Metadata
Title
The economic costs and health-related quality of life of people with HIV/AIDS in the Canary Islands, Spain
Authors
Julio Lopez-Bastida
Juan Oliva-Moreno
Lilisbeth Perestelo-Perez
Pedro Serrano-Aguilar
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2009
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/1472-6963-9-55

Other articles of this Issue 1/2009

BMC Health Services Research 1/2009 Go to the issue